Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Inclusion Criteria: 1. Sign a informed consent form and voluntarily join this study; 2. Esophageal squamous cell carcinoma diagnosed by histopathology or cytology; 3. Diagnosed as thoracic esophageal cancer by CT/MRI/EUS and clinically staged as T1b-3N1-2M0 or T3N0M0 (according to AJCC 8th edition); 4. Expected to achieve R0 resection; 5. Age ≥ 18 years old, regardless of gender; 6. ECOG PS 0-1; 7. Have not received any anti-tumor treatment for esophageal cancer in the past; 8. Plan to undergo surgical treatment after completion of neoadjuvant therapy; 9. No surgical contraindications; 10. The main organ functions are normal, including: 1. Blood routine examination: neutrocyte count ≥ 1.5 × 109/L Platelet count ≥ 100 × 109/L Hemoglobin ≥ 90 g/L 2. Blood biochemistry test: Total bilirubin ≤ 1.5 × ULN ALT ≤ 2.5×ULN，AST ≤ 2.5×ULN， Serum creatinine ≤ 1.5 × ULN, or creatinine clearance rate ≥ 50 mL/min (Cocheroft Gault formula, see Appendix 2) 3. Coagulation function: INR ≤ 1.5 × ULN APTT ≤ 1.5 × ULN 11. Women who have the ability to conceive or men whose spouses have the ability to conceive should use effective contraceptive measures during the study period; 12. The subjects showed good compliance and cooperated with follow-up visits; Exclusion Criteria: 1. Tumors or lymph nodes significantly invade adjacent organs of esophageal lesions; 2. Patients with supraclavicular lymph node metastasis; 3. Individuals at risk of perforation, fistula, etc; 4. There are uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage; 5. Poor nutritional status, BMI \< 18.5 Kg/m2； 6. Have a history of allergies to monoclonal antibodies, any components of Adebrelimab, paclitaxel, cisplatin, or other platinum based drugs in the past; 7. Have received or are currently receiving any of the following treatments: 1. Any radiotherapy, chemotherapy, or other anti-tumor drugs targeting tumors; 2. Within 2 weeks prior to the first use of the investigational drug, immunosuppressive or systemic hormone therapy was being used to achieve immunosuppressive effects; 3. Received attenuated live vaccine within 4 weeks prior to the first use of the investigational drug; 4. Having undergone major surgery or suffered severe trauma within 4 weeks prior to the first use of the investigational drug; 8. Suffering from any active autoimmune disease or history of autoimmune disease; 9. History of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation or allogeneic bone marrow transplantation; 10. There are clinical symptoms or diseases of the heart that have not been well controlled; 11. Severe infection (CTCAE\>grade 2) occurred within 4 weeks prior to the first use of the investigational drug; 12. Discovery of active pulmonary tuberculosis infection through medical history or CT examination; 13. Active hepatitis B and hepatitis C exist; 14. Diagnosed with other malignant tumors within 5 years prior to the first use of the investigational drug; 15. Pregnant or lactating women; 16. According to the researchers' assessment, there are other factors that may lead to the forced termination of the study midway.